Export
Model List of Essential Medicines
clear
Found 175 recommendations for 36 medicines and 0 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
-
Arsenic trioxide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
-
Asparaginase General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Bendamustine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Bleomycin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
-
Calcium folinate General information
SectionCytotoxic medicines- Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
-
Capecitabine General information
SectionCytotoxic medicines- Oral > Solid: 150 mg tablet; 500 mg tablet
-
Carboplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
IndicationsOther specified gliomas of brain Osteosarcoma of bone and articular cartilage of unspecified sites Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis -
Chlorambucil General information
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Cisplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
IndicationsOther specified gliomas of brain Malignant neoplasms of nasopharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx -
Cyclophosphamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid: 25 mg tablet; 50 mg tablet
IndicationsOther specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified malignant neoplasms of breast Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Rhabdomyosarcoma primary site Hodgkin lymphoma -
Cytarabine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
-
Dacarbazine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection
Indications -
Dactinomycin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Daunorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
-
Docetaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Doxorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
IndicationsMalignant neoplasms of breast Other specified malignant neoplasms of breast Hodgkin lymphoma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Kaposi sarcoma of unspecified primary site Diffuse large B-cell lymphomas -
Etoposide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsOther specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Hodgkin lymphoma Other specified malignant neoplasms of the ovary Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Retinoblastoma Myeloid leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites -
Fludarabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fluorouracil General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
-
Gemcitabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Hydroxycarbamide General information
SectionCytotoxic medicines- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
-
Ifosfamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
IndicationsOther specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Irinotecan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
-
Melphalan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Mercaptopurine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg tablet
-
Methotrexate General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
Indications -
Oxaliplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Paclitaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Pegaspargase General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial
Indications -
Procarbazine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg (as hydrochloride)
Indications -
Realgar-indigo naturalis formulation General information
SectionCytotoxic medicines- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
-
Tioguanine General information
SectionCytotoxic medicines- Oral > Solid: 40 mg
Indications -
Vinblastine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
-
Vincristine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
IndicationsOther specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Kaposi sarcoma of unspecified primary site -
Vinorelbine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
- Oral > Solid: 20 mg; 30 mg; 80 mg